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Abstract
Genome-wide association studies (GWAS) have identified thousands of loci associated wtih
complex traits, but it is challenging to pinpoint causal genes in these loci and to exploit subtle
association signals. We used tissue-specific quantitative interaction proteomics to map a network
of five genes involved in the Mendelian disorder long QT syndrome (LQTS). We integrated the
LQTS network with GWAS loci from the corresponding common complex trait, QT interval
variation, to identify candidate genes that were subsequently confirmed in Xenopus laevis oocytes
and zebrafish. We used the LQTS protein network to filter weak GWAS signals by identifying
single nucleotide polymorphisms (SNPs) in proximity to genes in the network supported by strong
proteomic evidence. Three SNPs passing this filter reached genome-wide significance after
replication genotyping. Overall, we present a general strategy to propose candidates in GWAS loci
for functional studies and to systematically filter subtle association signals using tissue-specific
quantitative interaction proteomics.
Introduction
General comment
Please keep the introduction to a general description of the rational and the method, no need
to go into details of which programs were used. But please make it clear what the
relationship between the LQTS genes used to construct the network and the associated genes
are. As written – and not being from this field, thus a good example for a non-expert reader
– it is not clear to me how the LQTS genes were determined and whether they overlap with
any of the 35 loci found in the GWAS. While this is explained in the Results it should
already be clear from the Introduction.
Do not call out Supplementary Information, but a particular file that should be part of the SI
Titles you sent (13 SI figures and 13 tables).
SI file needs to be revised;
Move methods to the main text file here and delete from the SI file.
Legend for the SI tables must be included in the Excel files of each table
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GWAS has been extremely successful in identifying loci associated with numerous diseases.
However, for a locus identified in a given trait it remains a major challenge to systematically
identify the specific gene involved in the phenotype especially if the biology of the trait in
question involves completely uncharted or largely incomplete pathways. To address this
issue we have developed an integrative approach combining GWAS data with quantitative
interaction proteomics to facilitate the annotation of associated loci. We apply this strategy
to identify candidates that represent critical regulators of the electrocardiographic QT
interval (the time between the end of the T wave and the onset of the Q wave in an
electrocardiogram depicting the heart's electrical cycle).
Prolongation of the electrocardiographic QT interval reflects abnormal myocardial
repolarization and is a risk factor for sudden cardiac death and drug-induced arrhythmias.
Long QT syndrome (LQTS) is a Mendelian disorder caused by genetic defects in one of 12
genes resulting in major prolongation of the QT interval (>40 msec)1. In addition, minor
variation of the QT interval (≈1-4 msec per allele) is a quantitative heritable trait in the
general population2,3 and recently 35 single nucleotide polymorphisms (SNPs) significantly
associated with this phenotype were identified4. Due to large spans of linkage
disequilibrium in the genome, these SNPs represent 35 loci (termed “common variant loci”
hereafter) encoding hundreds of genes. However, despite the fact that minor and major
variations of the QT interval represent different ends of the spectrum of the same phenotype,
no systematic approach has yet been employed to combine LQTS-informed and
experimentally derived pathways with associated SNPs to get broader insight into the
biology and genetic influences on cardiac repolarization in the general population.
Five of the 35 known common variant loci harbor Mendelian LQTS genes all of which are
cardiac ion channels or proteins regulating the ion channel function (Fig. 1a). Because
cardiac ion channels are thought to form large protein networks with hundreds of proteins
regulting the channels' functions through static and transient physical interactions, we
hypothesized that systematic pathway relationships between the associated loci could be
deduced by analyzing the protein network of the proteins corresponding to LQTS genes
(LQTS proteins hereafter). To test this hypothesis, we investigated the protein network of
five LQTS proteins in heart tissue using quantitative interaction proteomics and integrated
the network with GWAS data from an analysis of QT interval variation4. For breadth, we
chose LQTS proteins that were both ion channels and regulators of ion channels, as well as
proteins residing within and outside of the 35 common variant loci as the starting point of
the proteomics experiments (Fig. 1a). We cross-referenced the resulting interaction network
with the 35 established common variant loci associated with QT interval variation in the
general population to propose specific candidates for functional validation. We also used the
network data to filter sub genome-wide significant SNPs for replication genotyping (Fig.
1b). Overall, we expand our knowledge of the molecular components and genetic variants
driving cardiac repolarization. Importantly, we provide a general strategy and analytical
framework to annotate GWAS loci and filter weak association signals using tissue-specific
quantitative interaction proteomics.
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Results
Tissue-specific protein interaction network of LQTS genes
We chose five LQTS proteins as the starting point of our analysis (i.e., KCNQ1, KCNH2,
CACNA1C, SNTA1, CAV3)5–9. The proteins were immunoprecipitated from pooled lysates
of cardiac tissue from male mice, the precipitates were separated by SDS-PAGE followed
by in-gel trypsin digestion and analysis of the resulting peptide mixtures by nanoflow high-
performance liquid chromatography and subjected to tandem mass spectrometry (HPLC-
MS/MS)10–12 on a LTQ-Orbitrap Velos instrument using Higher-Collisional Dissociation
(HCD) fragmentation (Supplementary Figures 1 to 5)13. The complete set of raw MS files
were processed using the MaxQuant software suite (www.maxquant.org), where peptides
and proteins were identified using the Andromeda search engine at a false discovery rate
(FDR) below 0.01 and quantified using the label-free quantitation approach (all quantified
proteins and modification specific peptides are provided in Supplementary Tables 1 and 2).
We performed triplicate immunoprecipitations (IPs) of all LQTS proteins and compared
them to matched IgG control IPs, separating specific from nonspecific interactors by
applying a FDR cutoff of 0.0510,14 (Fig. 2a and b). As expected, the experimental triplicates
yielded highly reproducible results for protein signal intensities (Pearson r>0.8,
Supplementary Figure 6), and the LQTS proteins were among the most abundant proteins in
their respective protein networks (Fig 2b).
We identified 86 protein interactors of CACNA1C, 31 of KCNH2, 116 of KCNQ1, 104 of
SNTA1 and 333 for CAV3 (Supplementary Tables 3-7), and we show that at most (Online
Methods) of these proteins were nonspecific binders due to similarity of the LQTS proteins
in terms of subcellular localization in the plasma membrane. Four of the five affinity
purification datasets were enriched for known interaction partners15,16 (KCNQ1, P= 6.0e-3;
CACNA1C, P = 3.1e-5; CAV3, P = 8.9e-3; SNTA1, P = 5.0e-4, Online Methods), and the
number of interacting proteins match those reported in an analysis of CAV2 channels in rat
brain, where between 97 and 161 proteins interact specifically with the tested ion
channels17. In addition, the specificity, robustness, and high quality of the data was
confirmed by applying three alternative control procedures, which were not based on IgGs
(Online Methods and Supplementary Figure 7), and by providing biological replication in
five additional mouse hearts that had not been pooled (Online Methods, Supplementary
Figs. 8 and 9). After making individual quality controls of the pull-down datasets, we pooled
the interactions of all LQTS proteins to create an integrated LQTS protein network.
The LQTS protein network points to candidate genes in GWAS loci
A recent GWAS meta-analysis in >100,000 individuals of European ancestry identified 35
genome-wide significant (GWS) SNPs to be associated with QT interval variation in the
general population4, and the corresponding 35 common variant loci span 154 genes. A locus
was defined by identifying neighbor SNPs in linkage disequilibrium (r2>0.5) to the
associated SNP and expanding to the nearest recombination hotspot as previously
described18. Strikingly, excluding LQTS genes, twelve genes in the loci (PLN, ATP1B1,
UNC45B, TRAP1, TTN, CCDC141, ATP2A2, CAV1, CAV2, GOT2, ACTR1A, MYL3)
encoded proteins in the LQTS protein network derived here. The genes represent ten of the
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35 genome-wide significant loci (probability of such enrichment is P = 1.3e-6 using random
sampling taking into consideration locus architecture). As a control analysis, we made
analogous IPs in cardiac tissue lysates of five heart proteins involved in cardiomyopathies
(RYR2, ATP1A1, DSP, MYBPC3, and DMD, Supplementary Tables 9-13) and applied the
same protocols used for the LQTS proteins to derive a cardiomyopathy network. When
cross-referencing the genes represented in the control network with the 35 loci reported in
the GWAS meta-analysis, there was not a significant enrichment (P = 0.17, using random
sampling taking into consideration locus architecture), showing that the observed
enrichment was specific to the LQTS protein network and was not driven by highly heart-
expressed proteins that interact nonspecifically with the antibodies used in this study.
Importantly, the enrichment in QT loci is specific to the LQTS protein network and not a
feature of heart networks or networks involved in cardiac diseases in general. Therefore, our
results provide a strong mechanistic link at the level of protein networks between genes in
which rare mutations cause LQTS and 12 specific genes (in ten loci with a total of 79 genes,
Supplementary Figure 10) definitively associated with modest QT interval variation in the
general population.
Functional effects of candidate genes
ATP1B1 is encoded in a locus defined by rs10919070, the most associated SNP for QT
interval variation (P = 1.11e-31). We showed that ATP1B1 interacts with KCNH2,
CACNA1C, KCNQ1and CAV3. ATP1B1 is well-characterized as the β-subunit for the
Na+,K+-ATPase heterodimer. However, the α-subunit (ATP1A1) was not enriched in the
protein networks, suggesting an additional function of ATP1B1, which is independent of
ATP1A1.We tested the effect of ATP1B1on the KCNH2 channel by electrophysiological
measurements of heterologously expressed proteins in Xenopus laevis oocytes. Co-
expression of ATP1B1 shifts the peak of the current-voltage relationship by 10 mV to more
positive potentials, slows the channel inactivation kinetics, and right-shifts the voltage-
dependence of recovery from inactivation (Fig. 3). The same effects are observed in the
presence of an ATP1A1 inhibitor (Supplementary Figure 11). Interestingly, pull-down
experiments of ATP1A1 revealed no interaction to the KCNH2 channel (Supplementary
Table 10), and together these data show that ATP1B1 has a direct functional impact on the
KCNH2 channel properties independent of ATP1A1. We therefore propose a biological
mechanism through which common genetic variants near or in ATP1B1 affect QT interval
variation that has not previously been shown. To directly test the effect of ATP1B1 on
cardiac repolarization, we used optical voltage-mapping to probe cardiac electrophysiology
of ATP1B1 zebrafish knockdown animals, which are a well-established model of human
cardiac repolarization19. Morpholino knockdown of the zebrafish ortholog for ATP1B1
(atp1b1a) results in shorter action potential duration compared to wildtype (P = 0.002, Fig.
3). Together these results strongly support ATP1B1 as a candidate gene in the rs10919070
locus for further follow-up, as suggested by its interaction to KCNH2 and three other LQTS
proteins.
Filtering and augmenting subtle GWAS signals using the LQTS protein network
Similar to most other complex phenotypes, the SNPs associated with QT interval variation
explain only a minority of the heritability of this trait in the population. To investigate
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whether proteins in the LQTS network could be used to filter modestly associated SNPs and
identify a subset that is likely to influence the phenotype in the population, despite not being
significant in the GWAS. We excluded genes from the 35 loci definitively associated with
QT interval variation and made a composite test of genetic association across the remaining
genes represented in the LQTS network. We translated all identified mouse proteins to their
orthologous human genes and derived a set of association Z-scores for each gene, taking
SNP density and linkage disequilibrium across and surrounding each gene into
consideration18. Using a one-tailed Mann-Whitney rank-sum test, we compared the
distribution of association scores across genes represented in the protein networks to those
for all genes in the genome. Even after excluding the 12 genes from the definitively
associated loci, we found that the protein networks were significantly enriched for
association to QT interval variation (P = 1.5e-4, using a one-tailed rank sum test,
Supplementary Figure 12). This suggests that proteins in the networks point to genetic
variants important for QT interval variation which have so far been missed.
We used a combination of genetic and proteomic evidence to select 28 SNPs represented by
proteins in the networks for replication genotyping in four cohorts comprised of 17,692
independent samples in total. Specifically, SNPs were considered for replication genotyping
if the association significance in the GWAS meta-analysis was P<1e-3 and a protein in the
LQTS networks was encoded by a gene near the SNP. We also required that the protein
pointing to the SNP was abundant in the relevant LQTS IP hereby suggesting it is an in
important intrearction partner of a LQTS protein. The proteins that formed the basis for the
SNP selection were then plotted as a network along with information on the LQTS proteins
with which they interact (Fig 4a). Twenty five SNPs were successfully tested (see Online
Methods for filtering procedure), 18 were directionally consistent (probability of such
finding using the sign-test is P = 0.02), 7 were nominally significant in the replication cohort
(probability of such finding using permutation testing is P = 0.0003), and 3 reached genome-
wide significance when jointly analyzed with the recent GWAS meta-analysis (VCL –
rs10824026, P = 1.5e-9; SRL – rs889807, P = 1.2e-8 and TUFM/EIF3C/EIF3CL –
rs7498491, P = 2.2e-8, see Table 1 and SupplementaryNotes).
Interestingly, using the LQTS networks to guide replication experiments suggested new
insight into the biology of cardiac repolarization. First, SRL encodes the sarcolemmal Ca2+
binding protein sarcalumenin, which regulates Ca2+ reuptake into the sarcoplasmic
reticulum by interaction with the Ca2+-ATPase 2 (ATP2A2 also known as SERCA2)20. The
gene encoding ATP2A2 is itself in a locus significantly associated to QT interval variation
(rs17483, 3×10-12)4. The importance of SRL in cardiac physiology is evident from knockout
mice, in which ventricular depolarization is prolonged20. Our data show that the mouse
orthologs for ATP2A2 and SRL both interact with CAV3, and that ATP2A2 also interacts
with the LQTS calcium channel CACNA1C. Second, VCL encodes a cytoskeletal protein,
vinculin, which we show interacts with CAV3 and SNTA1. Although vinculin has
previously been related to dilated cardiomyopathy21, it has never been found to be involved
in QT interval variation. We furthermore confirmed the involvement of VCL in cardiac
repolarization by knockdown experiments of the ortholog, vcl, in zebrafish, which had a
direct effect on cardiac repolarization in vivo (Supplementary Figure 13). Knockdown of
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zebrafish orthologs of TUFM or EIF3C did not affect the action potential duration (data not
shown).
Thus, capialitizing on the LQTS protein network to filter modestly associated SNPs for
replication genotyping we identified three novel loci associated with QT interval variation in
the general population (Fig. 4b). For two of these loci functional in vivo evidence further
supports the specific gene we prioritized as driving the association signal.
Discussion
The methodological approach we have developed represents a strategy to functionally
annotate loci associated to a human trait through GWAS for which the causal genes have not
been identified, and to augment and filter modestly associated common variants. While it
has been shown previously that generic (i.e. non-tissue specific) in silico protein network
analyses based on public data is a powerful tool in interpreting common variants associated
to disease18, this study represents an important advance by using targeted proteomics
experiments in relevant tissue types22,23 to firmly establish the molecular interactions
between proteins in the relevant biological setting. In addition, to our knowledge, our
proteomics dataset represents the first analysis of the composition of protein networks
involved in rare Mendelian disease and its analogous common complex trait. Therefore, the
methodological and statistical framework outlined here may be applicable to a number of
other complex traits to propose candidate genes for validation in future genetic studies with
the ultimate goal of elucidating underlying biological systems and the specific causal genetic
determinants.
By testing the interaction networks of the five LQTS proteins one-by-one for genetic
entrichment in the GWAS data (Supplementary Figure 12) we show that, while individual
networks can yield statistically significant results, the power of our approach lies in the
integrated LQTS network obtained by pooling data from all five pull-downs. We note that
this might vary depending on the genetic power of the GWAS and it is not inconceivable
that similarly good results could be obtained in other traits with fewer proteins as the starting
point for the proteomics experiments. We also note that the approach outlined here is not
limited to complex diseases with a corresponding Mendelian phenotype. In theory any
protein known or hypothesized to be involed in the trait or biology of interest could be used
as the starting point of the proteomic analysis.
An interesting biological observation from our analysis together with the recent GWAS
meta-analysis4 is the involvement of calcium signaling in cardiac repolarization which is
suggested both from proteomics experiments, sequencing of LQTS patients, and meta-
analyses of genome-wide association studies, which all converge on a cluster of physically
interacting Ca2+ regulating proteins, thus providing new biological insight variations of the
QT interval in humans.
A limitation of our approach is that we use mouse heart tissue as the molecular components
of the biology of mouse and human cardiac repolarization might differ (see Online Methods
for discussion). For this reason, we used a variety of validation experiments including large
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and robust human genetic datasets and models systems widely accepted to be relevant to
human heart biology, to augment, complement, support, and filter the proteomics data.
These experiments firmly establish the value of the experimental and analytical framework
delineated here to gain insight into underlying molecular mechanisms of a common complex
human phenotype. This approach can be extended to other complex phenotypes to help
elucidate underlying biology and pinpoint candidate genes.
Online Methods
Tissue preparation and immunoprecipitations
The study was carried out following the Guide for the Care and Use of Laboratory Animals
published by the United States National Institutes of Health and the Directive 2010/63/EU of
the European Parliament. 6-8 weeks old male mice of strain C57BL6 were sacrificed by
cervical dislocation and their hearts were harvested and snap frozen in liquid nitrogen and
stored at -80 °C. Heart tissue was homogenized on a Precellys 24 and solubilized in ice-cold
lysis buffer containing protease and phosphatase inhibitors. Tissue lysates were centrifuged
to remove insoluble debris. For each tissue preparation produced, lysates derived from 5
mice were pooled and protein concentrations were measured by Quick Start Bradford Dye
Reagent (Biorad). Solubilized heart tissue lysate was pre-cleared with Dynabeads protein G
(Invitrogen) before incubation with primary antibody followed by binding to Dynabeads
protein G, using either anti-KCNQ1 (10 μl SC10646, Santa Cruz), anti-CACNA1C (2 μl
AC003, Alomone), anti-KCNH2 (2 μl AC062, Alomone), anti-CAV3 (2 μl ab2912, Abcam),
anti-SNTA1 (2 μl ab11425, Abcam) or control IgG (1.5 μl goat IgG: SC2028, 1.5 μl rabbit
IgG: SC2027, 1.5 μl mouse IgG: SC2025, Santa Cruz). After washing, bound proteins were
eluted with 1× sample buffer containing 100 mM dithiothreitol (70 °C, 3 min) and separated
by SDS-PAGE (4-15 % Bis-Tris gels, BioRad).
In-gel digestion
Separated proteins were fixed in the gel (40 ml water, 50 ml acetonitrile, 10 ml acetic acid,
10 min) and visualized with colloidal Coomassie staining (Invitrogen). Each gel lane was
excised and separated into four slices that were minced and destained (50 % 25 mM
ammonium bicarbonate, 50 % acetonitrile) in a thermomixer (3 times 20 min, 800 rpm,
room temperature (RT)). Gel dices were dehydrated (acetonitrile, 10 min, 800 rpm) followed
by reduction of disulfide bonds (10 mM dithiothreitol in 25 mM ammonium bicarbonate, 45
min, RT, 800 rpm) and alkylation of cysteines (55 mM chloro-acetamide in 25 mM
ammonium bicarbonate, 30 min, 24 °C in darkness, 800 rpm). After washing in 25 mM
ammonium bicarbonate the gel plugs were dehydrated in acetonitrile and proteins were
digested by trypsin (50 ul 12.5 ng/ul sequencing grade trypsin (Promega) in 25 mM
ammonium bicarbonate for 1 hour, followed by addition of 100 ul 25 mM ammonium
bicarbonate, left overnight at 37 °C). Trypsin activity was quenched by acidification of the
mixture with trifluoroacetic acid to pH∼2 and peptides were extracted from the gel plugs
with 30 % acetonitrile in 3 % trifluoroacetic acid (30 min, 800 rpm) followed by 80 %
acetonitrile in 0.5 % acetic acid (30 min, 800 rpm) and finally in 100 % acetonitrile13.
Organic solvents were removed by evaporation in a vacuum centrifuge. Extracted peptides
were purified on STAGE-tips with two C18 filters24.
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Mass-spectrometry, LC-MS/MS
Peptides were eluted from the STAGE tips into 96 well microtiterplates with 2×10 ul 40 %
acetonitrile in 0.5 % acetic acid and the acetonitrile was evaporated using a vacuum
centrifuge reducing the sample volume to 4 ul. The peptide mixtures were acidified with 0.1
% trifluoroacetic acid in 2 % acetonitrile to an end volume of 9 ul and analyzed by on-line
nanoflow LC-MS/MS. Peptide separation was performed by reversed-phase C18 HPLC on
an Easy nLC system (Thermo Fisher Scientific) loading 5 ul samples with a constant flow of
750 nl/min onto 15 cm long analytical columns, packed in-house with 3 um C18 beads, and
eluting peptides using a 135 min segmented gradient of increasing (5 %-80 %) buffer B (80
% acetonitrile in 0.5 % acetic acid) at a constant flow of 250 nl/min. The effluent from the
HPLC was directly electrosprayed into an LTQ Orbitrap Velos mass spectrometer (Thermo
Fisher Scientific) through a nano-spray ion source. The peptide mixture was analyzed by
full-scan MS spectra (m/z 300-2000, resolution 30,000) in the Orbitrap analyzer after
accumulation of 1,000,000 ions in the Orbitrap within a maximum fill-time of 1.000 ms with
the lock mass option enabled to improve mass accuracy25. For every full-scan the most
intense peptide ions were sequentially isolated (up to ten for every full-scan) and fragmented
by higher energy collisional dissociation (HCD) in the octopole collision cell and fragments
were recorded by the Orbitrap mass analyzer after accumulation of 50,000 ions with a
maximum fill-time of 250 ms and using a normalized collision energy of 40%.
Mass spectrometry data analysis
The acquired data was processed by MaxQuant (version 1.1.1.25) (Max-Planck Institute of
Biochemistry, Department of Proteomics and Signal Transduction, Munich)14, where
peptides and proteins are identified by the Andromeda search algorithm via matching of all
MS and MS/MS spectra against a target/decoy-version of the mouse IPI database v. 3.68
supplemented with reversed copies of all sequences as well as frequently observed
contaminants. Maximal MS/MS tolerance was 20 ppm, a maximum of 2 missed cleavages
was allowed and false discovery rates were set at 0.01 both for peptides and proteins.
Carbamidomethylated cysteines were set as a fixed modification, whereas N-pyroglutamine,
oxidation of methionine and N-terminal acetylation were searched as variable modifications.
Minimum peptide length was set at 6 amino acids. Statistical evaluation and filtering of the
resulting peptide datasets were performed in MaxQuant as previously described14. Protein
intensities were normalized and proteins were quantified between control and case
experiments by the MaxQuant label-free algorithm, resulting in LFQ (label-free
quantitation) protein intensities. The downstream analysis was performed with Excel
(Microsoft) and Perseus (Max-Planck Institute of Biochemistry, Department of Proteomics
and Signal Transduction, Munich) software. The triplicates of each bait IP were analyzed
against the five control IPs. Protein identifications were filtered for contaminants and
reverse hits. A minimum of three peptide identifications with at least one being uniquely
assigned to the particular protein, and protein identification in at least three
immunoprecipitations were required followed by log2 transformation of the LFQ intensities.
To perform statistical analysis of the label-free bait IP experiments versus control IP
experiments normal distributed values were imputed for missing values using a normal
distribution with width 0.3 and a downshift of the mean by 1.8 compared to distribution of
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all LFQ intensities. t-test based comparison of bait IPs versus control IPs were performed to
identify significant interactors with false discovery threshold set at 0.05 and a bend of the
curve value, S0, of 126. LFQ protein intensity ratios of bait relative to control was plotted
against the negative logarithmic P-value of the t-test as was a stipulated line representing the
permutation based false discovery rate separating specific from non-specific binders.
Significant interactors of the bait proteins were color coded in green and the rest were color
coded in blue. For the hierarchical clustering, LFQ intensities were Z-scored and average
linkage clustering was performed using Euclidian distance, and protein LFQ intensities were
color-coded with blue representing low intensities and yellow representing high intensities.
In general, the reporting of our mass spectrometry data acquisition, processing and search
results as well as sharing of all MS raw files have been done according to the Molecular and
Cellular Proteomics Guidelines. Raw mass spectrometric files in Thermo Scientific's *.raw
format are available for download through Tranche at http://proteomecommons.org using
the following Hash-key:
UpjhtcVZMgE8uKwuMa6G2qQokoYYdAs2mxUAYJmrPD6HWggQ
+WLr3DoMRQaM3wyNWHjEmFyJqjIcWxioc9NVGIRub0oAAAAAAAACiA==
with password LQT1LQT2LQT8LQT9LQT12
Association analyses
QT-IGC4—The QT-IGC consortium consists of 48 cohorts of European ancestry with QT-
interval and genome-wide genotype data (>100,000 individuals in total). Each cohort
contributed GWAS results from a linear regression of original QT-interval on genotype
using RR-interval, age and sex as covariates (individuals with QRS-duration > 120ms or
history of MI were excluded). The summary statistics (betas, standard errors and p-values)
on 2.5 million SNPs (either directly genotyped or imputed) were then combined in a meta-
analysis using the software MANTEL27. The non-genomic-control-corrected results were
used in this analysis to match what is reported in the accompanying QT-IGC study
(λGC=1.069).
To test the joint set of proteins (737 proteins in total, 436 unique proteins) derived from all
LQTS protein networks for containing more GWS hits than chance expectation, taking into
account that multiple GWS proteins were represented in more than one network, we
simulated 10,000,000 random selections of 5 networks (each of the same number of proteins
represented in the individual networks) from all genes in the genome. For each random
selection of 737 total proteins, we counted the number of GWS hits. We then report an
empirical P-value for the probability of selecting 22 or more GWS hits (22 represent the fact
that some of the 12 GWS proteins were representing in multiple networks). To derive a P-
value for each individual network we performed a hypergeometric test, since we did not
need to account for proteins being represented multiple times.
The joint test for enrichment in association performed on the remaining proteins in the
complexes (those that did not achieve genome-wide significance) was carried out as
described previously18. In order to control for linkage disequilibrium (LD) between genes,
we broke the genome into LD blocks as defined by recombination hotspots. We then scored
Lundby et al. Page 10
Nat Methods. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
each block with the best association Z score achieved over that block (association data was
from the QTIGC meta-analysis)4. This score was then corrected for the number of SNPs
tested in the block using linear regression in R. The residuals from the regression were used
as the corrected scores for each block, and genes were assigned scores according to the
blocks they overlap. To test a group of proteins for enrichment in association, we compared
the unique set of scores derived from the group of proteins to the unique set of scores for all
genes in the genome using a 1-tailed rank-sum test, with the alternative hypothesis being
that the group of proteins has higher association scores than scores from all genes in the
genome.
Assessing the contribution of heart expression to association results
Because regions of the genome associated to QT interval variation are likely to code for
heart-expressed genes, we assessed the probability that our association results (number of
GWS proteins represented in the LQTS networks as well as enrichment in sub-genome-wide
scores) were due to enrichment for association in heart-expressed proteins rather than
network-specific proteins. Based on organ-wide proteomic mapping of phosphoproteins in
rat hearts28, we collected a dataset of 2000 proteins expressed in heart tissue. We assessed
the likelihood of identifying 22 GWS proteins in a random selection of 5 networks (each of
the same number of proteins represented in the individual networks – 737 proteins in total).
After 1,000,000 permutations, we found the probability of selecting >=22 proteins to be
0.00536.
Replication genotyping and analysis
We selected 28 SNPs to replicate that met the following criteria: they are in LD with a gene
that codes for one of the proteins pulled down in the 5 complexes, and either their
association P-value was <1e-4 (18 SNPs) or was <1e-3 and the protein of interest passed a
threshold for being abundantly present in one of the complexes (4 proteins). The selected
SNPs were then genotyped or looked up in four cohorts: 5,731 independent samples were
genotyped in the SMART cohort, and betas, standard errors and P-values were collected for
the from the LifeLines cohort (n=4,865), the POSPER/PHASE cohort (n=5,135) and the
RS3 cohort (n=1,961), for which the QT interval duration had been measured (in
milliseconds) but the results had not been included in the QT-IGC meta-analysis. Each
analysis performed a linear regression of the original QT measurement on genotype using
RR-interval, age and sex as covariates. Individuals with QRS duration > 120ms or positive
history of myocardial infarction were removed.
Cohort descriptions
SMART29—The Secondary Manifestations of ARTerial disease study. SMART is a
prospective cohort study among patients aged 18-74 years who are referred to the University
Medical Center Utrecht, The Netherlands, because of atherosclerotic vascular disease or for
treatment of atherosclerotic risk factors30. The objective of the SMART study is to
determine the prevalence of asymptomatic arterial disease and risk factors in patients
presenting with a manifestation of arterial disease or known risk factor, and to study future
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cardiovascular events and their predictors in these at-risk patients. Wet-lab genotyping was
carried out by KBiosciences, Hertfordshire, UK, using proprietary KASPar PCR technique.
LifeLines31—LifeLines is a multi-disciplinary prospective population-based cohort study
examining in a unique three-generation design the health and health-related behaviours of
165,000 persons living in the North East region of The Netherlands. It employs a broad
range of investigative procedures in assessing the biomedical, socio-demographic,
behavioural, physical and psychological factors which contribute to the health and disease of
the general population, with a special focus on multimorbidity and complex genetics. The
LifeLines Cohort Study, and generation and management of GWAS genotype data for the
LifeLines Cohort Study is supported by the Netherlands Organization of Scientific Research
NWO (grant 175.010.2007.006), the Economic Structure Enhancing Fund (FES) of the
Dutch government, the Ministry of Economic Affairs, the Ministry of Education, Culture
and Science, the Ministry for Health, Welfare and Sports, the Northern Netherlands
Collaboration of Provinces (SNN), the Province of Groningen, University Medical Center
Groningen, the University of Groningen, Dutch Kidney Foundation and Dutch Diabetes
Research Foundation. We thank Behrooz Alizadeh, Annemieke Boesjes, Marcel
Bruinenberg, Noortje Festen, Ilja Nolte, Lude Franke, Mitra Valimohammadi for their help
in creating the GWAS database, and Rob Bieringa, Joost Keers, René Oostergo, Rosalie
Visser, Judith Vonk for their work related to data-collection and validation. The authors are
grateful to the study participants, the staff from the LifeLines Cohort Study and Medical
Biobank Northern Netherlands, and the participating general practitioners and pharmacists.
LifeLines Scientific Protocol Preparation: Rudolf de Boer, Hans Hillege, Melanie van der
Klauw, Gerjan Navis, Hans Ormel, Dirkje Postma, Judith Rosmalen, Joris Slaets, Ronald
Stolk, Bruce Wolffenbuttel; LifeLines GWAS Working Group: Behrooz Alizadeh, Marike
Boezen, Marcel Bruinenberg, Noortje Festen, Lude Franke, Pim van der Harst, Gerjan
Navis, Dirkje Postma, Harold Snieder, Cisca Wijmenga, Bruce Wolffenbuttel.
PROSPER/PHASE32,33—All data come from the PROspective Study of Pravastatin in
the Elderly at Risk (PROSPER). A detailed description of the study has been published
elsewhere. PROSPER was a prospective multicenter randomized placebo-controlled trial to
assess whether treatment with pravastatin diminishes the risk of major vascular events in
elderly. Between December 1997 and May 1999, we screened and enrolled subjects in
Scotland (Glasgow), Ireland (Cork), and the Netherlands (Leiden). Men and women aged
70-82 years were recruited if they had pre-existing vascular disease or increased risk of such
disease because of smoking, hypertension, or diabetes. A total number of 5,804 subjects
were randomly assigned to pravastatin or placebo. A large number of prospective tests were
performed including Biobank tests and cognitive function measurements. Resting 12 lead
ECGs were recorded at baseline and annually thereafter and were analyzed using the
University of Glasgow analysis program. A whole genome wide screening has been
performed in the sequential PHASE project with the use of the Illumina 660K beadchip. Of
5,763 subjects DNA was available for genotyping. Genotyping was performed with the
Illumina 660K beadchip, after QC (call rate <95%) 5,244 subjects and 557,192 SNPs were
left for analysis. These SNPs were imputed to 2.5 million SNPs based on the HAPMAP built
36 with MACH imputation software. PROSPER is supported by an investigator initiated
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grant from Bristol-Myers Squibb, the Netherlands Heart Foundation (grant 2001 D 032,
JWJ), EU 7th framework (grant 223004), the Netherlands Genomics Initiative (Netherlands
Consortium for Healthy Aging grant 050-060-810).
RS334—The Rotterdam Study III (RS-III) is a prospective population-based cohort study.
The cohort comprises 3,932 subjects aged 45 years and older, living in the Ommoord district
in Rotterdam, the Netherlands. The rationale and design of the RS have been described in
detail elsewhere. The Medical Ethics Committee of Erasmus Medical Center approved the
study and written consent was obtained from all participants. Electrocardiograms were
recorder on ACTA electrocardiographs (ESAOTE, Florence, Italy) and digital
measurements of the QRS intervals were made using the Modular ECG Analysis System
(MEANS). All RS-III participants with available DNA were genotyped using Illumina
Human 610 Quad array at the Department of Internal Medicine, Erasmus Medical Center
following manufacturer's protocols. Participants with call rate < 97.5%, excess autosomal
heterozygosity, sex mismatch, or outlying identity-by-state clustering estimates were
excluded. After quality control 2,082 RS-III participants were included. Of these, 1961
participants were included in this study. The Rotterdam Study (RS) is supported by the
Erasmus Medical Center and Erasmus University Rotterdam; The Netherlands Organization
for Scientific Research; The Netherlands Organization for Health Research and
Development (ZonMw); the Research Institute for Diseases in the Elderly; The Netherlands
Heart Foundation; the Ministry of Education, Culture and Science; the Ministry of Health
Welfare and Sports; the European Commission; and the Municipality of Rotterdam. Support
for genotyping was provided by The Netherlands Organization for Scientific Research
(NWO) (175.010.2005.011, 911.03.012) and Research Institute for Diseases in the Elderly
(RIDE).
For the SMART data (the only data which we received as raw genotypes), we ran a linear
regression in Plink35 to test for association to the duration of the QT interval in the same
manner as was done in the QT-IGC meta-analysis as well as the other 3 cohorts, controlling
for age, sex and RR-interval and excluding individuals with QRS duration > 120 or past
history of MI.
The meta-analysis was done with the program METAL27 using effect size estimates and
standard errors. We removed 3 SNPs due to missing data in ≥3 of the 4 cohorts, resulting in
a total of 25 SNPs analyzed. These results are reported in the main text and as part of Figure
3d and Table 1. Association results are expressed in terms of a 1-tailed p-value in the
replication cohort and a 2-tailed p-value when folded in with the meta-analysis. We assessed
the results as follows: first, we counted the number of SNPs that were nominally significant
(P < 0.05) in the replication cohort. 7 were nominally significant. 1.25 SNPs by chance are
expected to be nominally significant, and this therefore represents an enrichment at
P=0.0003 using a binomial test. We then did a sign-test for directional consistency, and
found that the effect sizes of 18/25 SNPs were directionally consistent with QTIGC (P =
0.02). Then, we considered the replication p-value in addition to direction of effect by
counting the number of SNPs that improved the QT-IGC meta-analysis p-value when jointly
considered. 11 improved the original QT-IGC p-value, whereas on average 7.6 are expected
by chance based on simulation (P = 0.03).
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Electrophysiology and data analysis
Preparation and injection of cRNA into Xenopus oocytes, purchased from EcoCyte
Bioscience (Castrop-Rauxel, Germany) were done as described36. cDNAs were verified by
sequencing. GeneBank accession numbers of the clones used were NM_000238 for
hKCNH2a and NM_001677 for hATP1B1. Currents were recorded from three batches of
oocytes injected with hKCNH2a, hKCNH2a+hATP1B1 or hATP1B1 cRNA with hKCNH2a
and hATP1B1 injected at a 1:1 molar ratio from a holding potential of −80 mV.
Electrophysiological recordings were performed at room temperature (22°C–24°C) 3 days
after injection in Kulori medium (90 mM NaCl, 4 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 5
mM HEPES, pH 7.4) using a two-electrode voltage clamp amplifier (CA-1B, Dagan,
Minneapolis, MN, USA). Data analysis was performed using Pulse (HEKA, Lambrecht,
Germany), Igor Pro 4.04 (Wavemetrics, Lake Oswego, OR, USA), and GraphPad Prism
(GraphPad Software Inc, San Diego, CA, USA). All values are displayed as mean ± SEM.
Current–voltage (I/V) relations were obtained from the step-protocol by plotting the outward
current at the end of the second test-pulse as a function of the test-potential. Inactivation
kinetics was evaluated by the time constant derived from a monoexponential fit to the
decaying phase of the current. The voltage-dependence of activation, inactivation and
recovery from inactivation was determined by fitting normalized currents versus test
potentials to a two-state Boltzmann distribution of the form I(V) = 1/(1+exp[(V½ − V)/a]),
where V½ is the potential for half-maximal activation and a is the slope factor. The number
of independent experiments is indicated by n. Comparison of the biophysical properties in
the presence and absence of hATP1B1 were performed using an unpaired t-test with P <0 .
05 being considered significant.
Zebrafish experiments
All zebrafish experiments were performed in accordance with approved Institutional Animal
Care and Use Committee (IACUC) protocols. TuAB or Ekwill wild type zebrafish strains
were reared according to standard techniques. At the single cell stage, fertilized oocytes
were injected with 1-10ng of antisense morpholino oligos targeting the transcription
initiation sites of ATP1B1a37, VCL38, TUFM (5′ -
GAATTTTATAACTTACCGGAGAGGC – 3′) or EIF3C (5′ –
GTCTTCTCCACAAACTCACTGCTGT – 3′) dissolved in Danieau's solution (58 mM
NaCl, 0.7mM KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, 5.0 mM HEPES pH 7.6). Controls
were injected with Danieau's solution alone. Embryo hearts were microdissected, stained
with di-4-ANEPPS (Invitrogen) and imaged on a CCD Camera (Cardio-SMQ, Red Shirt
Imaging) at 1000 frames per second as previously described21. Cardiac motion was arrested
with the use of 15uM blebbistatin (Sigma), field pacing was employed to control beating
frequency (Grass S48 Stimulator).
For both ATP1B1 and VCL, two different morpholinos were used and knockdown was
demonstrated. For ATP1B1 the phenotype was reversed by injection of the wild type mRNA.
For the morpholino targets where we did not observe any phenotype (TUFM and EIF3C) we
have not yet proven knockdown, nor is there any literature-based evidence of the effect. We
have added this information to the text.
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Alternative control procedures not based on IgGs
We identified five proteins involved in cardiomyopathy (RYR2, ATP1A1, DSP, MYBPC3,
and DMD), where we performed immunoprecipitations in heart tissue using the same
methodology as for the five LQTS proteins. These proteins were analyzed analogously to
the five LQTS bait IPs: i) we made triplicate IPs, ii) we separated the precipitated proteins
by SDS-PAGE, iii) we in-gel digested the proteins, and iv) we analyzed the peptides by LC-
MS/MS analysis (See Supplementary Tables S9-S13 for the proteins identified in the
pulldowns).
We analyzed the LQTS protein network dataset using the cardiomyopathy pull-down data as
the control. The resulting LQTS complexes were compared to the complexes obtained by
IgG control experiments (see Supplementary Figure 7). The cardiomyopathy control data
was analyzed and applied in three different ways:
First, we used the median protein intensity of the five cardiomyopathy IPs to compare the
LQTS bait IPs to a ‘general’ cardiac protein control (labeled CM1-5_median in
Supplementary Figure 7). Second, we used the average protein intensity of the five
cardiomyopathy IPs to compare the LQTS bait IPs to another ‘general’ cardiac protein
control (labeled CM1-5_average in Supplementary Figure 7). Third, we tested each of the
LQTS IPs against the cardiomyopathy IP it is most similar to, where similarity is evaluated
by hierarchical clustering of the data (labeled CM1 or CM2 in Supplementary Figure 7). Our
results show that there is a high degree of consistency between the proteins interacting with
each of the LQTS proteins when using either IgG controls or different cardiomyopathy
protein controls. Using the median of all 5 cardiomyopathy pull-downs as the control, we
identify between 87% and 97% (average 91%) of the interaction partners identified with the
IgG control procedure. Using the average of all 5 cardiomyopathy pull-downs as the control,
we identify between 83% and 90% (average 87%) of the interaction partners identified using
the IgGs as the control. Testing each of the LQTS pull-downs against the most similar
cardiomyopathy pull-down, we identify between 68% and 91% (average 77%) of the same
interaction partners identified using the IgG control procedure. These results strongly
support that the interactors identified for the five LQT baits are robust to the use of several
different control procedures - including procedures based on IgGs.
Biological replication in 5 Additional Mouse Hearts
To test if our proteomics dataset is affected by the use of pooled tissue samples we
generated data from individual hearts and compared those to a pooled sample. We isolated
hearts from five male mouse siblings, and prepared homogenates for the individual hearts.
We made four sets of IPs using antibodies against KCNQ1, KCNH2, CACNA1C and IgGs
from each of the individual heart lysates as well as from a pooled sample. All sample
preparation was done as described earlier with the exception that the mass spectrometric
analysis was performed on Q-Exactive instrumentation instead of LTQ Orbitrap Velos. In
Supplementary Figure 8 we show the hierarchical clustering of all identified proteins by
their label-free quantified (LFQ) protein intensities. IPs from pooled heart samples cluster
with the analogous IPs from the individual hearts. These results show that the interaction
partners we identify with the different baits using technical replicates (pooled hearts), are
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highly comparable to the interaction partners identified using biological replicates (hearts
1-5).
Correlation plots of LFQ intensities for the four sets of IPs (KCNQ1, KCNH2, CACNA1C
and IgGs) are further supporting the high reproducibility between experiments
(Supplementary Figure 9). For each plot the Pearson correlation coefficient is provided in
the upper left corner. The average correlation coefficient between a pooled heart sample and
the individual heart samples is 0.91 (or 0.93 for CACNA1C; 0.94 for IgG; 0.86 for KCNH2;
and 0.91 for KCNQ1). We note that the correlation coefficients are comparable to the ones
that we reported in the manuscript for the pooled samples, showing that the pooled samples
are indeed adequate for identifying reproducible interactions using quantitative interaction
proteomics.
Assessing the contribution of subcellular localization to association results
To assess if the subcellular localization of the immunoprecipitated proteins contribute
significantly to the association signal we made pairwise comparisons of the three ion
channel pull-downs. On average only 4% of all interaction partners are repetitive between
pairs of ion channel pull-downs (specifically, the percentage of repetitive interaction
partners is 6% for KCNH2 and KCNQ1; 4% for KCNH2 and CACNA1C; and 2% for
KCNQ1 and CACNA1C; respectively). Thus, our data shows that protein interactors
residing in the same sub-cellular domains are, at the very most, comprising ∼4% of the
interactions we report. Notably, the genes corresponding to proteins that are repetitive
between pairs of ion channel pull-downs are only weakly enriched in genome-wide
significant loci (P= 0.041). This observation clearly demonstrates that this class of proteins
does not drive the statistical enrichment of genes in genome-wide significant loci we
observe across the LQTS protein complexes.
Potential weaknesses of using mouse hearts for proteomics experiments
A potential limitation of our study is that we make use of mouse heart tissue as the
molecular components of the biology of mouse and human cardiac repolarization might
differ. For this reason, we used a variety of validation experiments, including very large and
robust human genetic datasets, to augment, complement, and filter the proteomics data.
Specifically, we i) applied several statistical tests of enrichment of association to QT
prolongation in a cohort of 100,000 humans, all of which showed very significant
enrichment of the complexes to human QT phenotypes, and ii) we used replication
genotyping in 17,500 additional individuals to confirm a handful of human genetic variants
proposed by the complexes to be involved in cardiac repolarization. We went further and
functionally validated a number of the specific interaction partners in well-established model
systems of human cardiac repolarization by performing electrophysiological experiments in
Xenopus oocytes, as well as in-vivo knockdowns in zebrafish. Although there are limitations
to our analysis, our results clearly show that this does not preclude the identification of
novel pathway relationships, new specific genes, and novel genetic variants relevant to
human cardiac repolarization.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Editorial summary
The results of genome wide association studies are combined with quantitative
interaction proteomics to narrow down the list of putative causal disease genes and filter
modest association signals.
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Figure 1. General design and experimental workflow of our integrated genetic and proteomic
study
a) Five of the 12 LQTS genes reside in loci definitely associated with QT interval variation
in the general population through GWAS. b) Protein interaction networks for LQTS proteins
(purple boxes where physical interactions are shown as black lines) are resolved in cardiac
tissue by quantitative interaction proteomics (top). Interaction partners of the LQTS proteins
that reside in GWAS loci are identified and functionally validated (green boxes). Other
interaction partners supported by strong proteomic evidence (yellow boxes), point to SNPs
that can be prioritized for replication genotyping.
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Figure 2. Quantitative interaction proteomics of five Mendelian LQTS proteins
a) Hierarchical cluster analysis of proteins identified in immunoprecipitation experiments
visualizes the experimental specificity and reproducibility. Proteins are color-coded
according to their mass-spectrometry signal intensity. Triplicates of the LQTS protein
immunoprecipitations (a-c) are shown. The highlighted yellow areas indicate that each
group of triplicate experiments immunoprecipitates a specific cluster of proteins. b) Volcano
plots, representing the LQTS protein IPs versus IgG control IPs, show negative
logarithmized t-test derived P-values (-log10(P)) as function of logarithmized ratios of
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average protein intensities (log2) for the LQTS protein relative to control. A hyperbolic
curve indicates a false discovery rate cut-off of 0.05 and separates specific from nonspecific
interactors. All points represent a protein. Purple indicates a LQTS protein, green represent
proteins specifically interacting with the LQTS proteins, and blue represents nonspecific
interactors.
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Figure 3. Proteomic annotation of GWAS loci coupled to experimental follow up identifies
ATP1B1 as a QT variation candidate gene
a) Distribution of association Z-scores for genes represented in the interactomes (grey bars)
to a background distribution of all genes in the genome (black line). The x-axis represents Z-
scores assigned to genes corrected for SNP density and linkage disequilibrium structure. The
insert shows a zoom-in of the tail of the distribution, illustrating that the distribution is
significantly enriched for genes at GWS loci (P = 1.3e-6, using random sampling, see
Online Methods). b) Representative current traces recorded from KCNH2 (left) and
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KCNH2 +ATP1B1 (right) proteins heterologously expressed in Xenopus laevis oocytes by
two-electrode voltage clamp. Step currents were elicited using the depicted voltage clamp
protocol with 1s pulses to test potentials ranging from −80 to +40 mV followed by
deactivation (tail) current measurements at −60 mV. c) Current-voltage relationships were
constructed by normalizing the steady-state currents measured at the end of each voltage
step to the maximum outward current and plotting it as function of the test potential (n = 11
for KCNH2, n = 9 for KCNH2+ATP1B1). d) Channel inactivation kinetics were evaluated
from currents elicited from the indicated pulse protocol. Inactivation time constants
measured at +60 mV are shown for KCNH2 in absence (n = 10) or presence (n = 14) of
ATP1B1. Data points are mean ± SEM. e) Cardiac action potential after Morpholino
knockdown of zebrafish atp1b1a (APD80 = 256±20 msec) compared to carrier injected
controls (APD80 = 321±21 msec), n = 13 independent samples per condition. * represents
P<0.05. f) Superimposed normalized traces are shown for one representative sample for
atp1b1a knockdown (red) and control conditions (blue).
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Figure 4. Integrative analysis of the LQTS protein network and GWAS data
a) Depiction of the interactions identified in the proteomics experiments between the LQTS
proteins (purple) and proteins encoded by genes in genome-wide significant common variant
loci (greene) as well as proteins encoded by genes that lie near the 28 SNPs filtered for
replication genotyping (yellow). The proteins are plotted according to the best genetic
association P-value of their corresponding genes in the horizontal direction after taking the
negative 10 based logarithm of the P-value and in this depiction (for visualization purposes)
we do not correct the P-value for multiple hypothesis testing and LD in order to preserve the
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true association score as determined in the GWAS. Interactions are represented by grey
lines,. The dashed red line indicates the threshold for GWS (corresponding to a P-value of
5.0e-8). b) An overview of proteins in the LQTS protein network encoded by genes in all 38
loci (green) significantly assocaied to QT variation in this study and in Arking et al.4. The
five proteins with yellow halos represent the three SNPs that became genome-wide
significant after replication genotyping in this study (locus 1, rs7498491: EIF3C, EIF3CL,
TUFM; locus 2, rs889807: SRL; locus 3, rs10824026: VCL).
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